Details of the Researcher

PHOTO

Masayuki Kanamori
Section
Graduate School of Medicine
Job title
Associate Professor
Degree

  • 博士（医学）（東北大学）

e-Rad No.
60420022

Research History 5

  • 2017/07 - Present
    Tohoku University Graduate School of Medicine　Department of Neurosurgery　Associate professor

  • 2015/07 - 2017/06
    Tohoku University Graduate School of Medicine　Department of Neurosurgery　Lecturer

  • 2010/10 - 2013/04
    Tohoku University Graduate School of Medicine　Department of Neurosurgery　assistant professor

  • 2005/10 - 2008/09
    Tohoku University Graduate School of Medicine　Department of Neurosurgery　assistant professor

  • 2001/09 - 2004/01
    University of California, San Francisco　Neurological surgery　visiting postdoctoral fellow

Education 1

  • Tohoku University　Graduate School of Medicine

    - 2001/03

Committee Memberships 2

  • 一般社団法人 脳腫瘍の外科学会　評議員

    2017/09 - Present

  • 一般社団法人 日本脳神経外科学会　代議員

    2015/09 - Present

Professional Memberships 10

  • 日本小児脳神経外科学会

  • 日本脳神経外科手術と機器学会

  • 日本分子脳神経外科学会

  • 日本脳神経CI学会

  • 日本脳卒中の外科学会

  • 日本脳卒中学会

  • 日本脳腫瘍の外科学会

  • 日本脳腫瘍病理学会

  • 日本脳腫瘍学会

  • 日本脳神経外科学会

︎Show all ︎Show first 5

Research Interests 4

  • surgical treatment for brain tumor

  • pediatric brain tumor

  • molecular diagnosis

  • glioma

Research Areas 1

  • Life sciences / Neurosurgery / brain tumor

Papers 105

  1. Coexistence of an intracranial germ cell tumor with a growing arteriovenous fistula: a case report. Peer-reviewed

    Ishida T, Endo H, Saito R, Kanamori M, Sato K, Matsumoto Y, Endo T, Fujimura M, Tominaga T

    2019/04

  2. Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI. International-journal Peer-reviewed

    Ichiyo Shibahara, Ryuta Saito, Yoshinari Osada, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Shunji Mugikura, Mika Watanabe, Teiji Tominaga

    Journal of neuro-oncology　141　(2)　337-345　2019/01

    DOI： 10.1007/s11060-018-03036-4 　

    ISSN： 0167-594X

    More details Close

    PURPOSE: Intracranial glioblastomas with simultaneous spinal lesions prior to chemoradiation therapy or craniotomy, defined as initial spinal metastasis, are not well understood. Herein, we investigated intracranial glioblastoma and demonstrated the importance of spinal screening using gadolinium enhanced spinal magnetic resonance imaging (Gd-MRI). METHODS: Consecutive adult patients with intracranial glioblastoma were treated between 2010 and 2014 and received spinal screening using Gd-MRI. Spinal screening was performed regardless of spine-related symptoms, and patients presenting with and without initial spinal metastasis (spinal and non-spinal groups, respectively) were compared based on patient demographics, tumor characteristics, radiological and molecular features, and overall survival (OS). RESULTS: During the study period, 116 glioblastoma cases were treated and 87 of these (76%) underwent spinal screening. Among these patients, 11 (13%) were included in the spinal group, and 76 (87%) were included in the non-spinal group. All patients of the spinal group were free of symptoms related to spinal lesions. Compared with the non-spinal group, intracranial lesions of the spinal group presented higher incidences of intracranial dissemination and were located at subventricular zones (P = 0.0012 and 0.020, respectively). MIB-1 labeling index, molecular alterations such as IDH1 mutation, TERT promoter mutation, and immunoreactivity of ATRX and MGMT did not differ between two groups. OS was significantly shorter in the spinal group than in the non-spinal group (P = 0.0054). CONCLUSIONS: This study revealed a relatively high incidence of spinal metastasis. A subset of glioblastoma patients benefited from spinal screening, through which early detection of asymptomatic spinal metastasis was achieved.

  3. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Peer-reviewed

    Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M

    Neuro Oncol　2018/11

  4. SMART (stroke-like migraine attacks after radiation therapy) syndrome responded to steroid pulse therapy: Report of a case and review of the literature. International-journal Peer-reviewed

    Wenting Jia, Ryuta Saito, Masayuki Kanamori, Naoya Iwabuchi, Masaki Iwasaki, Teiji Tominaga

    eNeurologicalSci　12　1-4　2018/09

    DOI： 10.1016/j.ensci.2018.05.003 　

    More details Close

    This report presents a case of stroke-like migraine attacks after radiation therapy (SMART) syndrome in a 31-year-old man in whom symptoms and radiological findings resolved with steroid pulsed therapy and reviews the literatures with special emphasis on the use of steroids against SMART syndrome. The patient had a past history of left temporal anaplastic astrocytoma and was treated with surgery followed by local 72 Gy radiation therapy and chemotherapy using Nimustine Hydrochloride. Four years after the surgery, he was suffering from subacute progressing symptoms of headache, right hemianopia, right hemiparesis and aphasia from 2 to 4 days before admission to our hospital. At first he was diagnosed as symptomatic epilepsy but after extensive examination, the final diagnosis was SMART syndrome. His symptoms soon improved with steroid pulse therapy. In the literature, steroid pulse therapy is not necessarily a standard of care for SMART syndrome, but it seemed to decrease the need of biopsy. As the lesions of SMART syndrome require differential diagnosis from recurrences, biopsy was performed in some cases. However, lack of benefit and possible detriment is reported with biopsy of SMART lesions. Through this experience we suggest that steroid pulse therapy may provide speedy recovery from symptoms, and it should be considered before other invasive investigations or treatments.

  5. Indications for salvage surgery during treatment for intracranial germ cell tumors. International-journal Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Mika Watanabe, Masashi Chonan, Ryuta Saito, Yoji Yamashita, Yoshikazu Ogawa, Yukihiko Sonoda, Teiji Tominaga

    Journal of neuro-oncology　138　(3)　601-607　2018/07

    DOI： 10.1007/s11060-018-2827-3 　

    ISSN： 0167-594X

    More details Close

    This study retrospectively reviewed our single institute experience to clarify the optimal indication and timing of salvage surgery. Retrospective analysis of 159 consecutive cases with germ cell tumors identified 20 cases with salvage surgery. These cases were classified based on the radiological response to neoadjuvant treatment before salvage surgery into increase (growing group, five cases), no change (stable group, seven cases), and decrease (shrinkage group, eight cases) in tumor size. Changes in tumor markers, histological findings, and the pattern of failure after salvage surgery were reviewed. Growing teratoma syndrome (GTS) is defined as enlargement of tumor consisting of mature teratoma after chemotherapy with normalization of tumor markers. In growing group, two cases presented GTS, whereas other three cases did not fulfill the criteria for GTS. All cases in stable and shrinkage group had elevated levels of tumor markers at presentation and decreased levels after neoadjuvant treatment. Histologically, sparse components of mature teratoma with extensive fibrosis were found in cases with GTS and seven of eight cases in shrinkage group, whereas mature teratoma without fibrosis was found in six of seven cases in stable group. Six cases recurred after salvage surgery. We identified three factors as risks for recurrence after salvage surgery, as follows: (1) growing lesion which did not fulfill the criteria for GTS, (2) non-normalized level of tumor marker before salvage surgery, and (3) residual germinoma component. In conclusion, salvage surgery is recommended for patients with GTS, or with normalized tumor markers in stable or shrinkage group.

  6. Clinical Features of Precocious, Synchronous, and Metachronous Brain Metastases and the Role of Tumor Resection. International-journal Peer-reviewed

    Ichiyo Shibahara, Masayuki Kanamori, Takashi Watanabe, Akihiro Utsunomiya, Hiroyoshi Suzuki, Ryuta Saito, Yukihiko Sonoda, Hidefumi Jokura, Hiroshi Uenohara, Teiji Tominaga

    World neurosurgery　113　e1-e9-e9　2018/05

    DOI： 10.1016/j.wneu.2017.10.145 　

    ISSN： 1878-8750

    More details Close

    OBJECTIVE: The purpose of this study was to clarify clinical features, outcomes, and the role of tumor resection in precocious, synchronous, and metachronous brain metastases. METHODS: Brain metastases were found before primary cancer detection in the precocious group, within 2 months after primary cancer detection in the synchronous group, and 2 months or later after primary cancer detection in the metachronous group. RESULTS: Of 471 patients with brain metastases, 93 (20%) were included in the precocious group, 76 (16%) in the synchronous group, and 302 (64%) in the metachronous group. The precocious group tended to be symptomatic, show a low Karnofsky Performance Status, and have a large single tumor, infrequent extracranial metastases, and frequent tumor resection compared with the other 2 groups. There were no differences in overall survival from the detection of brain metastases among the 3 groups in univariate and multivariate analyses. Of 471 cases, 97 (21%) underwent surgeries. Among this surgical cohort, overall survival from surgery was significantly shorter in the precocious group than in the metachronous group (P = 0.039). After adjustment for age, sex, tumor size, primary cancer, and the Graded Prognostic Assessment score, the hazard ratio for metachronous metastases was 0.52 (confidence interval, 0.29-0.95; P = 0.035). CONCLUSIONS: The timing of brain metastasis diagnosis is not a modifiable factor but affects patient demographics and treatment strategies. In particular, the precocious group is a unique subset of brain metastases that require special consideration during clinical decision making.

  7. [A Case of Ventriculoperitoneal Shunt Dysfunction in an Adult Secondary to Constipation]. Peer-reviewed

    Nakamura L, Saito R, Kanamori M, Morita T, Tashiro R, Tominaga T

    No shinkei geka. Neurological surgery　46　(5)　385-389　2018/05

    DOI： 10.11477/mf.1436203739 　

    ISSN： 0301-2603

    More details Close

    INTRODUCTION: Ventriculoperitoneal(VP)shunts function because of the pressure differential between the intracranial space and the peritoneal cavity. Although chronic constipation is often a cause of VP shunt dysfunction in children, it is not well recognized in adults. We present a case of shunt dysfunction that not only resolved after resolution of constipation but also resulted in overdrainage. CASE REPORT: A 28-year-old woman who had a VP shunt placed 11 years prior for hydrocephalus was referred to our department because of an enlarged ventricle diagnosed with computed tomography(CT). She had a previous history of pineal germinoma and a VP shunt was placed to treat the associated hydrocephalus. At presentation, she complained of headache and somnolence. Shunt dysfunction was suspected, but no problem was detected in the shunt system, including pressure settings. As constipation was detected, we treated this condition. Soon after, her symptoms resolved and ventricle size normalized. She was discharged without any deficit, but overdrainage was detected with CT obtained 1 month later. CONCLUSION: Although constipation is not a common cause of shunt dysfunction in adult patients, it is important to consider to avoid unnecessary shunt revision. In the present case, resolution of chronic constipation resulted in resolution of shunt dysfunction. This suggests the importance of resolution of constipation in case of shunt adjustment, even in adult cases.

  8. Parapharyngeal neuroglial heterotopia appearing as high uptake on 18F–FDG PET: case report and literature review of radiographical findings Peer-reviewed

    Masayuki Kameyama, Tomohiro Kawaguchi, Hidetaka Niizuma, Takenori Ogawa, Kenichi Watanabe, Toshiaki Hayashi, Kanako Sato, Masayuki Kanamori, Mika Watanabe, Yukio Katori, Shigeo Kure, Teiji Tominaga

    Acta Neurochirurgica　160　(4)　801-809　2018/04/01

    Publisher: Springer-Verlag Wien

    DOI： 10.1007/s00701-017-3403-x 　

    ISSN： 0942-0940 0001-6268

    eISSN： 0942-0940

  9. Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia. Peer-reviewed

    Kajitani T, Kanamori M, Saito R, Watanabe Y, Suzuki H, Watanabe M, Kure S, Tominaga T

    Brain tumor pathology　35　(2)　114-122　2018/04

    DOI： 10.1007/s10014-018-0316-1 　

    ISSN： 1433-7398

  10. Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Peer-reviewed

    Masayuki Kanamori, Masamitsu Maekawa, Ichiyo Shibahara, Ryuta Saito, Masashi Chonan, Miki Shimada, Yukihiko Sonoda, Toshihiro Kumabe, Mika Watanabe, Nariyasu Mano, Teiji Tominaga

    Brain tumor pathology　35　(2)　90-96　2018/04

    DOI： 10.1007/s10014-018-0317-0 　

    ISSN： 1433-7398

    More details Close

    The 2016 World Health Organization classification of tumors of the central nervous system was recently revised. Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and chromosome 1p/19q codeletion are especially important for both the integrated diagnosis and the determination of surgical strategy. To establish a method for intraoperative molecular diagnosis, a simple, rapid method was developed for the measurement of 2-hydroxyglutarate (2-HG), a specific oncometabolite formed in the presence of IDH gene mutation, using liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS). This method requires only 10 min to measure the level of 2-HG from tissue preparation to completion of examination. Using this method, the level of 2-HG was analyzed in 105 patients with diffuse infiltrating glioma, and showed that IDH mutated glioma had significantly higher level of 2-HG compared to IDH wild-type glioma. Receiver operating characteristic curve analysis showed the area under the curve, sensitivity, and specificity were 0.9815, 97.5, and 100%, respectively. In contrast, tumor grade and presence of chromosome 1p/19q codeletion in the IDH mutated glioma could not be predicted from the level of 2-HG. Measurement of 2-HG level using LC/ESI-MS/MS can provide rapid and accurate information of mutation status in the IDH gene.

  11. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model. International-journal Peer-reviewed

    Shinya Haryu, Ryuta Saito, Wenting Jia, Takuhiro Shoji, Yui Mano, Aya Sato, Masayuki Kanamori, Yukihiko Sonoda, Oltea Sampetrean, Hideyuki Saya, Teiji Tominaga

    Journal of neuro-oncology　136　(1)　23-31　2018/01

    DOI： 10.1007/s11060-017-2621-7 　

    ISSN： 0167-594X

    More details Close

    Expression of CD44 in glioma cells was previously correlated with tumor grade and is considered a stem cell marker. CD44 stabilizes the cystine-glutamate transporter (xCT) and inhibits apoptosis in cancer stem cells (CSCs). Recently it was found that Sulfasalazine (SSZ), an anti-inflammatory drug, acts as an inhibitor of xCT and therefore has potential as a targeted therapy for CSCs. In this study, we tested an efficacy of SSZ against glioma stem cell model developed in rats. As poor penetration of blood-brain barrier resulted in insufficient efficacy of systemic SSZ treatment, SSZ was delivered locally with convection-enhanced delivery (CED). In vitro, expression of CD44 in glioma cells and efficacy of SSZ against glioma cells and glioma stem cells were confirmed. SSZ demonstrated anti-proliferative activity in a dose dependent manner against these cells. This activity was partially reversible with the addition of antioxidant, N-acetyl-L-cysteine, to the medium. In vivo, CED successfully delivered SSZ into the rat brain parenchyma. When delivered at 5 mM concentration, which was the highest possible concentration when SSZ was dissolved in water, CED of SSZ resulted in almost no tissue damage. Against highly malignant bRiTs-G3 brain tumor xenografted rat model; the glioma stem cell model, CED of SSZ at 5 mM concentration induced apoptosis and prolonged survival. Consequently, CED of SSZ induced glioma stem cell death without evidence of tissue damage to normal brain parenchyma. This strategy may be a promising targeted treatment against glioma stem cells.

  12. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Peer-reviewed

    Ichiyo Shibahara, Yukihiko Sonoda, Hiroyoshi Suzuki, Akifumi Mayama, Masayuki Kanamori, Ryuta Saito, Yasuhiro Suzuki, Shoji Mashiyama, Hiroshi Uenohara, Mika Watanabe, Toshihiro Kumabe, Teiji Tominaga

    Brain tumor pathology　35　(1)　10-18　2018/01

    DOI： 10.1007/s10014-017-0302-z 　

    ISSN： 1433-7398

    More details Close

    Pilocytic astrocytomas and low-grade gliomas are more common compared with glioblastomas in patients with neurofibromatosis 1 (NF1). A recent genome-wide analysis has shown frequent NF1 gene alterations in the mesenchymal subtype of a glioblastoma; however, little is known about clinicopathological features of glioblastomas in NF1 patients (NF1 glioblastomas). We analyzed four NF1 glioblastomas. Radiographical and intraoperative findings showed well-circumscribed tumors from surrounding brain. Pathological analysis presented a paucity of processes with an eosinophilic cytoplasm, bizarre nuclei, xanthomatous-like appearance, multinucleated giant cells, and histiocytoid appearance. During the follow-up period, one patient died at 49 months and others remained alive for 60, 87, and 106 months; thus, patients with NF1 glioblastoma presented a relatively favorable survival. None of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation. We identified that NF1 glioblastoma is a unique subset of glioblastoma.

  13. Factors contributing to surgical intervention for subacute subdural hematoma enlargement in patients with mild head injuries Peer-reviewed

    Yosuke Akamatsu, Tohru Sasaki, Masayuki Kanamori, Shinsuke Suzuki, Hiroshi Uenohara, Teiji Tominaga

    Neurological Surgery　45　(9)　771-779　2017/09/01

    Publisher: Igaku-Shoin Ltd

    DOI： 10.11477/mf.1436203591 　

    ISSN： 1882-1251 0301-2603

  14. Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study Peer-reviewed

    Yukihiko Sonoda, Ichiyo Shibahara, Ken-ichiro Matsuda, Ryuta Saito, Tomoyuki Kawataki, Masaya Oda, Yuichi Sato, Hirokazu Sadahiro, Sadahiro Nomura, Toshio Sasajima, Takaaki Beppu, Masayuki Kanamori, Kaori Sakurada, Toshihiro Kumabe, Teiji Tominaga, Hiroyuki Kinouchi, Hiroaki Shimizu, Kuniaki Ogasawara, Michiyasu Suzuki

    JOURNAL OF NEURO-ONCOLOGY　134　(1)　83-88　2017/08

    DOI： 10.1007/s11060-017-2488-7 　

    ISSN： 0167-594X

    eISSN： 1573-7373

  15. Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Teiji Tominaga

    NEUROSURGICAL REVIEW　40　(3)　469-477　2017/07

    DOI： 10.1007/s10143-016-0804-x 　

    ISSN： 0344-5607

    eISSN： 1437-2320

  16. Intraoperative Visualization of Subependymal Arteries at the Atrium Supplying the Descending Motor Pathway Peer-reviewed

    Mitsuto Hanihara, Sumito Sato, Ichiyo Shibahara, Ryuta Saito, Masayuki Kanamori, Yukihiko Sonoda, Hiroyuki Kinouchi, Teiji Tominaga, Toshihiro Kumabe

    WORLD NEUROSURGERY　101　296-303　2017/05

    DOI： 10.1016/j.wneu.2017.02.022 　

    ISSN： 1878-8750

    eISSN： 1878-8769

  17. Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas Peer-reviewed

    Shintaro Fukushima, Satoshi Yamashita, Hisato Kobayashi, Hirokazu Takami, Kohei Fukuoka, Taishi Nakamura, Kai Yamasaki, Yuko Matsushita, Hiromi Nakamura, Yasushi Totoki, Mamoru Kato, Tomonari Suzuki, Kazuhiko Mishima, Takaaki Yanagisawa, Akitake Mukasa, Nobuhito Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga, Motoo Nagane, Toshihiko Iuchi, Koji Yoshimoto, Masahiro Mizoguchi, Kaoru Tamura, Keiichi Sakai, Kazuhiko Sugiyama, Mitsutoshi Nakada, Kiyotaka Yokogami, Hideo Takeshima, Yonehiro Kanemura, Masahide Matsuda, Akira Matsumura, Kazuhiko Kurozumi, Keisuke Ueki, Masahiro Nonaka, Akio Asai, Nobutaka Kawahara, Yuichi Hirose, Tatusya Takayama, Yoichi Nakazato, Yoshitaka Narita, Tatsuhiro Shibata, Masao Matsutani, Toshikazu Ushijima, Ryo Nishikawa, Koichi Ichimura

    ACTA NEUROPATHOLOGICA　133　(3)　445-462　2017/03

    DOI： 10.1007/s00401-017-1673-2 　

    ISSN： 0001-6322

    eISSN： 1432-0533

  18. Extremely Late Recurrence 21 Years after Total Removal of Immature Teratoma: A Case Report and Literature Review Peer-reviewed

    Yui Mano, Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Mika Watanabe, Yukihiko Sonoda, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　57　(1)　51-56　2017/01

    DOI： 10.2176/nmc.cr.2016-0241 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  19. Hypoxia-like tissue injury and glial response contribute to Balo concentric lesion development Peer-reviewed

    Yoshiki Takai, Tatsuro Misu, Shuhei Nishiyama, Hirohiko Ono, Hiroshi Kuroda, Ichiro Nakashima, Ryuta Saito, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Shunji Mugikura, Mika Watanabe, Masashi Aoki, Kazuo Fujihara

    NEUROLOGY　87　(19)　2000-2005　2016/11

    DOI： 10.1212/WNL.0000000000003308 　

    ISSN： 0028-3878

    eISSN： 1526-632X

  20. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models Peer-reviewed

    Rong Zhang, Ryuta Saito, Yui Mano, Akira Sumiyoshi, Masayuki Kanamori, Yukihiko Sonoda, Ryuta Kawashima, Teiji Tominaga

    DRUG DELIVERY　23　(8)　2780-2786　2016/10

    DOI： 10.3109/10717544.2015.1081994 　

    ISSN： 1071-7544

    eISSN： 1521-0464

  21. Sarcoma-like tumor originating from oligodendroglioma Peer-reviewed

    Takuhiro Shoji, Ryuta Saito, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　33　(4)　255-260　2016/10

    DOI： 10.1007/s10014-016-0268-2 　

    ISSN： 1433-7398

    eISSN： 1861-387X

  22. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion Peer-reviewed

    Tomohiro Kawaguchi, Yukihiko Sonoda, Ichiyo Shibahara, Ryuta Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga

    JOURNAL OF NEURO-ONCOLOGY　129　(3)　505-514　2016/09

    DOI： 10.1007/s11060-016-2201-2 　

    ISSN： 0167-594X

    eISSN： 1573-7373

  23. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models Peer-reviewed

    Takuhiro Shoji, Ryuta Saito, Masashi Chonan, Ichiyo Shibahara, Aya Sato, Masayuki Kanamori, Yukihiko Sonoda, Toru Kondo, Naoto Ishii, Teiji Tominaga

    NEURO-ONCOLOGY　18　(8)　1120-1128　2016/08

    DOI： 10.1093/neuonc/now023 　

    ISSN： 1522-8517

    eISSN： 1523-5866

  24. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy Peer-reviewed

    Koichi Ichimura, Shintaro Fukushima, Yasushi Totoki, Yuko Matsushita, Ayaka Otsuka, Arata Tomiyama, Tohru Niwa, Hirokazu Takami, Taishi Nakamura, Tomonari Suzuki, Kohei Fukuoka, Takaaki Yanagisawa, Kazuhiko Mishima, Yoichi Nakazato, Fumie Hosoda, Yoshitaka Narita, Soichiro Shibui, Akihiko Yoshida, Akitake Mukasa, Nobuhito Saito, Toshihiro Kumabe, Masayuki Kanamori, Teiji Tominaga, Keiichi Kobayashi, Saki Shimizu, Motoo Nagane, Toshihiko Iuchi, Masahiro Mizoguchi, Koji Yoshimoto, Kaoru Tamura, Taketoshi Maehara, Kazuhiko Sugiyama, Mitsutoshi Nakada, Keiichi Sakai, Yonehiro Kanemura, Masahiro Nonaka, Akio Asai, Kiyotaka Yokogami, Hideo Takeshima, Nobutaka Kawahara, Tatsuya Takayama, Masahiro Yao, Mamoru Kato, Hiromi Nakamura, Natsuko Hama, Ryuichi Sakai, Toshikazu Ushijima, Masao Matsutani, Tatsuhiro Shibata, Ryo Nishikawa

    ACTA NEUROPATHOLOGICA　131　(6)　889-901　2016/06

    DOI： 10.1007/s00401-016-1557-x 　

    ISSN： 0001-6322

    eISSN： 1432-0533

  25. Bone regeneration after chemotherapy for vault lymphoma Peer-reviewed

    Yosuke Akamatsu, Masayuki Kanamori, Hiroshi Uenohara, Teiji Tominaga

    BMJ Case Reports　2016　2016/02/22

    Publisher: BMJ Publishing Group

    DOI： 10.1136/bcr-2015-213524 　

    ISSN： 1757-790X

  26. Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation Peer-reviewed

    Masayuki Kanamori, Hiroyoshi Suzuki, Hidehiro Takei, Yukihiko Sonoda, Hiroshi Uenohara, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　33　(1)　50-56　2016/01

    DOI： 10.1007/s10014-015-0231-7 　

    ISSN： 1433-7398

    eISSN： 1861-387X

  27. Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells Peer-reviewed

    Rong Zhang, Ryuta Saito, Ichiyo Shibahara, Shinichiro Sugiyama, Masayuki Kanamori, Yukihiko Sonoda, Teiji Tominaga

    JOURNAL OF NEURO-ONCOLOGY　126　(2)　235-242　2016/01

    DOI： 10.1007/s11060-015-1968-x 　

    ISSN： 0167-594X

    eISSN： 1573-7373

  28. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models Peer-reviewed

    Masashi Chonan, Ryuta Saito, Takuhiro Shoji, Ichiyo Shibahara, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Toshiaki Kikuchi, Naoto Ishii, Teiji Tominaga

    NEURO-ONCOLOGY　17　(11)　1453-1462　2015/11

    DOI： 10.1093/neuonc/nov090 　

    ISSN： 1522-8517

    eISSN： 1523-5866

  29. Diffuse large B cell lymphoma of the cranial vault: two case reports Peer-reviewed

    Ryosuke Tashiro, Masayuki Kanamori, Hiroyoshi Suzuki, Akihiro Utsunomiya, Kuniaki Meguro, Hiroshi Uenohara, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　32　(4)　275-280　2015/10

    DOI： 10.1007/s10014-015-0225-5 　

    ISSN： 1433-7398

    eISSN： 1861-387X

  30. Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors Peer-reviewed

    Hirokazu Takami, Shintaro Fukushima, Kohei Fukuoka, Tomonari Suzuki, Takaaki Yanagisawa, Yuko Matsushita, Taishi Nakamura, Hideyuki Arita, Akitake Mukasa, Nobuhito Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga, Keiichi Kobayashi, Motoo Nagane, Toshihiko Iuchi, Kaoru Tamura, Taketoshi Maehara, Kazuhiko Sugiyama, Mitsutoshi Nakada, Yonehiro Kanemura, Masahiro Nonaka, Kiyotaka Yokogami, Hideo Takeshima, Yoshitaka Narita, Soichiro Shibui, Yoichi Nakazato, Ryo Nishikawa, Koichi Ichimura, Masao Matsutani

    JOURNAL OF NEURO-ONCOLOGY　124　(1)　23-32　2015/08

    DOI： 10.1007/s11060-015-1809-y 　

    ISSN： 0167-594X

    eISSN： 1573-7373

  31. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients Peer-reviewed

    Masayuki Kanamori, Tsuyoshi Higa, Yukihiko Sonoda, Shohei Murakami, Mina Dodo, Hiroshi Kitamura, Keiko Taguchi, Tatsuhiro Shibata, Mika Watanabe, Hiroyoshi Suzuki, Ichiyo Shibahara, Ryuta Saito, Yoji Yamashita, Toshihiro Kumabe, Masayuki Yamamoto, Hozumi Motohashi, Teiji Tominaga

    NEURO-ONCOLOGY　17　(4)　555-565　2015/04

    DOI： 10.1093/neuonc/nou282 　

    ISSN： 1522-8517

    eISSN： 1523-5866

  32. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas Peer-reviewed

    Yukihiko Sonoda, Ichiyoo Shibahara, Tomohiro Kawaguchi, Ryuta Saito, Masayuki Kanamori, Mika Watanabe, Hiroyoshi Suzuki, Toshihiro Kumabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　32　(2)　99-104　2015/04

    DOI： 10.1007/s10014-014-0211-3 　

    ISSN： 1433-7398

    eISSN： 1861-387X

  33. Rosette-forming Glioneuronal Tumor: Rare Case Presented with Spontaneous Disappearance of Contrast Enhancement. Peer-reviewed

    Shinya Haryu, Ryuta Saito, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Mika Watanabe, Faruk Tonga, Teiji Tominaga

    NMC case report journal　2　(2)　65-67　2015/04

    DOI： 10.2176/nmccrj.2014-0077 　

    More details Close

    This report presents rosette-forming glioneuronal tumor (RGNT) of the tectum in a 24-year-old woman in whom spontaneous disappearance of contrast enhancement (CE) on magnetic resonance (MR) imaging was observed during 9-year follow-up period before therapeutic intervention. MR imaging obtained 9 years ago when she first visited local hospital with headaches showed a mass of the brain stem with CE. Follow-up MR imaging showed disappearance of CE without tumor growth. Nine years later, she was admitted to our hospital with headache and nausea, due to obstructive hydrocephalus. She underwent endoscopic third ventriculostomy (ETV) and tumor biopsy. Histological study revealed RGNT. To our knowledge, this is the first report presenting that the RGNT may show spontaneous disappearance of CE without tumor growth. It is unclear what this phenomenon means, however, knowledge of this phenomenon may be helpful for correct diagnosis and for follow up of RGNT.

  34. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy Peer-reviewed

    Ichiyo Shibahara, Ryuta Saito, Rong Zhang, Masashi Chonan, Takuhiro Shoji, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Masahiko Kanehira, Toshiaki Kikuchi, Takanori So, Takashi Watanabe, Hiroaki Takahashi, Erina Iwabuchi, Yuetsu Tanaka, Yukiko Shibahara, Hironobu Sasano, Naoto Ishii, Teiji Tominaga

    MOLECULAR CANCER　14　41　2015/02

    DOI： 10.1186/s12943-015-0307-3 　

    ISSN： 1476-4598

  35. Malignant clinical features of anaplastic gliomas without IDH mutation Peer-reviewed

    Ichiyo Shibahara, Yukihiko Sonoda, Takuhiro Shoji, Masayuki Kanamori, Ryuta Saito, Tomoo Inoue, Tomohiro Kawaguchi, Yoji Yamashita, Takashi Watanabe, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Teiji Tominaga

    NEURO-ONCOLOGY　17　(1)　136-144　2015/01

    DOI： 10.1093/neuonc/nou112 　

    ISSN： 1522-8517

    eISSN： 1523-5866

  36. Practical surgical indicators to identify candidates for radical resection of insulo-opercular gliomas Peer-reviewed

    Tomohiro Kawaguchi, Toshihiro Kumabe, Ryuta Saito, Masayuki Kanamori, Masaki Iwasaki, Yon Yamashita, Yukihiko Sonoda, Teiji Tominaga

    JOURNAL OF NEUROSURGERY　121　(5)　1124-1132　2014/11

    DOI： 10.3171/2014.7.JNS13899 　

    ISSN： 0022-3085

    eISSN： 1933-0693

  37. Efficacy of halo-vest fixation in the assessment and prediction of the effectiveness of permanent fixation in a patient with basilar invagination with ambiguous vertebral instability Peer-reviewed

    Shin-Ichiro Osawa, Shinsuke Suzuki, Toru Sasaki, Masayuki Kanamori, Hiroshi Uenohara

    Neurological Surgery　42　(10)　931-935　2014/10/01

    Publisher: Igaku-Shoin Ltd

    DOI： 10.11477/mf.1436200007 　

    ISSN： 1882-1251 0301-2603

  38. Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas Peer-reviewed

    Shintaro Fukushima, Ayaka Otsuka, Tomonari Suzuki, Takaaki Yanagisawa, Kazuhiko Mishima, Akitake Mukasa, Nobuhito Saito, Toshihiro Kumabe, Masayuki Kanamori, Teiji Tominaga, Yoshitaka Narita, Soichiro Shibui, Mamoru Kato, Tatsuhiro Shibata, Masao Matsutani, Ryo Nishikawa, Koichi Ichimura

    ACTA NEUROPATHOLOGICA　127　(6)　911-925　2014/06

    DOI： 10.1007/s00401-014-1247-5 　

    ISSN： 0001-6322

    eISSN： 1432-0533

  39. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma Laboratory investigation Peer-reviewed

    Masayuki Kanamori, Atsuo Kikuchi, Mika Watanabe, Ichiyo Shibahara, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Toshihiro Kumabe, Shigeo Kure, Teiji Tominaga

    JOURNAL OF NEUROSURGERY　120　(6)　1288-1297　2014/06

    DOI： 10.3171/2014.3.JNS131505 　

    ISSN： 0022-3085

    eISSN： 1933-0693

  40. Transformation of adult cerebellar pilocytic astrocytoma to glioblastoma Peer-reviewed

    Takashi Sasaki, Ryuta Saito, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　31　(2)　108-112　2014/04

    DOI： 10.1007/s10014-013-0154-0 　

    ISSN： 1433-7398

    eISSN： 1861-387X

  41. Preservation of the Long Insular Artery to Prevent Postoperative Motor Deficits after Resection of Insulo-opercular Glioma: Technical Case Reports Peer-reviewed

    Masaki Iwasaki, Toshihiro Kumabe, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Yukihiko Sonoda, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　54　(4)　321-326　2014/04

    DOI： 10.2176/nmc.cr2012-0361 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  42. The Association of Subventricular Zone Involvement at Recurrence with Survival after Repeat Surgery in Patients with Recurrent Glioblastoma Peer-reviewed

    Yukihiko Sonoda, Ryuta Saito, Masayuki Kanamori, Toshihiro Kumabe, Hiroshi Uenohara, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　54　(4)　302-309　2014/04

    DOI： 10.2176/nmc.oa.2013-0226 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  43. Subarachnoid Hemorrhage after an Ischemic Attack Due to a Bacterial Middle Cerebral Artery Dissecting Aneurysm: Case Report and Literature Review Peer-reviewed

    Atsushi Saito, Tomohiro Kawaguchi, Emiko Hori, Masayuki Kanamori, Shinjitsu Nishimura, Seiya Sannohe, Mitsuomi Kaimori, Tatsuya Sasaki, Michiharu Nishijima

    NEUROLOGIA MEDICO-CHIRURGICA　54　(3)　196-200　2014/03

    DOI： 10.2176/nmc.cr2012-0251 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  44. Early response to chemotherapy as an indicator for the management of germinoma-like tumors of the pineal and/or suprasellar regions Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Shunji Mugikura, Shoki Takahashi, Teiji Tominaga

    JOURNAL OF CLINICAL NEUROSCIENCE　21　(1)　124-130　2014/01

    DOI： 10.1016/j.jocn.2013.05.014 　

    ISSN： 0967-5868

    eISSN： 1532-2653

  45. Concentration rather than dose defines the local brain toxicity of agents that are effectively distributed by convection-enhanced delivery Peer-reviewed

    Rong Zhang, Ryuta Saito, Yui Mano, Masayuki Kanamori, Yukihiko Sonoda, Toshihiro Kumabe, Teiji Tominaga

    JOURNAL OF NEUROSCIENCE METHODS　222　131-137　2014/01

    DOI： 10.1016/j.jneumeth.2013.11.004 　

    ISSN： 0165-0270

    eISSN： 1872-678X

  46. Treatment Results of Glioblastoma during the Last 30 Years in a Single Institute Peer-reviewed

    Toshihiro Kumabe, Ryuta Saito, Masayuki Kanamori, Masashi Chonan, Yui Mano, Ichiyo Shibahara, Tomohiro Kawaguchi, Hideaki Kato, Yoji Yamashita, Yukihiko Sonoda, Jun Kawagishi, Hidefumi Jokura, Mika Watanabe, Ryuichi Katakura, Takamasa Kayama, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　53　(11)　786-796　2013/11

    DOI： 10.2176/nmc.oa2013-0212 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  47. Clinical significance and limitations of repeat resection for pediatric malignant neuroepithelial tumors Peer-reviewed

    Tomohiro Kawaguchi, Toshihiro Kumabe, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Yukihiko Sonoda, Teiji Tominaga

    JOURNAL OF NEUROSURGERY-PEDIATRICS　12　(4)　309-316　2013/10

    DOI： 10.3171/2013.6.PEDS12606 　

    ISSN： 1933-0707

  48. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. International-journal Peer-reviewed

    Ichiyo Shibahara, Yukihiko Sonoda, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Takashi Watanabe, Chikashi Ishioka, Teiji Tominaga

    Neuro-oncology　15　(9)　1151-9　2013/09

    DOI： 10.1093/neuonc/not066 　

    ISSN： 1522-8517

    More details Close

    BACKGROUND: Glioblastoma carries a poor prognosis primarily because of its high rate of recurrence. The ability to predict the recurrence pattern and timing would be highly useful for determining effective treatment strategies. We examined the correlation between prognostic factors and the pattern of recurrence in patients with primary glioblastoma. In particular, we examined whether there was a correlation between the expression of CD133 and glioblastoma recurrence. METHODS: We retrospectively analyzed 112 patients with primary glioblastoma. The timing and pattern (local or distant) of the initial recurrence were obtained from medical records. To identify factors predictive of recurrence, we examined CD133 expression by Western blots and immunohistochemistry, clinical (age, sex, KPS, Ki67 labeling index, surgery, ventricular entry) and genetic (IDH1, 7p, 9p, 10q, MGMT) factors. RESULTS: Of the 112 patients, 99 suffered recurrence. The first recurrence was local in 77 patients and distant in 22 patients. Among the factors to predict the pattern of recurrence, CD133 expression was significantly higher in distant than in local recurrence. Of the factors to predict the timing of recurrence, high CD133 expression was associated with shorter time to distant recurrence in both univariate and multivariate analyses (P = .0011 and P = .038, respectively). CONCLUSIONS: The expression of CD133 may be a predictor of the pattern and timing of recurrence of primary glioblastoma.

  49. Medial posterior choroidal artery territory infarction associated with tumor removal in the pineal/tectum/thalamus region through the occipital transtentorial approach Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Shunji Mugikura, Shoki Takahashi, Teiji Tominaga

    CLINICAL NEUROLOGY AND NEUROSURGERY　115　(8)　1257-1263　2013/08

    DOI： 10.1016/j.clineuro.2012.11.020 　

    ISSN： 0303-8467

  50. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Ichiyo Shibahara, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Hiroyoshi Suzuki, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　30　(3)　151-159　2013/07

    DOI： 10.1007/s10014-012-0119-8 　

    ISSN： 1433-7398

  51. Infarction of the lateral posterior choroidal artery territory after manipulation of the choroid plexus at the atrium: causal association with subependymal artery injury. International-journal Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Yukihiko Sonoda, Masayuki Kanamori, Shunji Mugikura, Shoki Takahashi, Teiji Tominaga

    Journal of neurosurgery　119　(1)　158-63　2013/07

    DOI： 10.3171/2013.2.JNS121221 　

    ISSN： 0022-3085

    More details Close

    OBJECT: The atrium of the lateral ventricle is often affected by tumors, and some patients with these tumors suffer neurological deficits, including hemiparesis after surgery. The authors of this study investigated the possible mechanisms causing the relatively high incidences of ischemic complications associated with surgery approaching the atrium of the lateral ventricle. METHODS: Clinical records and radiological images of 28 patients were retrospectively studied. These patients had their lateral ventricles opened at the atrium during the resection of gliomas as well as other nonbenign brain tumors, and were treated for gliomas at our tertiary referral center in the Tohoku district, Japan, between January 2008 and December 2010. RESULTS: Routine postoperative diffusion-weighted MR images obtained within 72 hours after surgery detected infarction in the periatrial/periventricular regions in 7 patients, presumably corresponding to the lateral posterior choroidal artery (LPChA) territory. Five of these 7 patients suffered neurological sequelae with varying severities. The choroid plexus at the atrium was coagulated to achieve hemostasis during the surgery in all of these patients. Detailed analysis of microangiograms revealed ventriculofugal arteries arising from the lateral ventricle. Damage of the subependymal artery that supplies the ventriculofugal arteries caused by coagulation of the choroid plexus at the atrium probably resulted in the infarction in these patients. CONCLUSIONS: Neurosurgeons must be aware of the possibility of LPChA territory infarction during surgery in the atrial or periatrial regions caused by subependymal artery obstruction after manipulating or coagulating the choroid plexus near the atrium.

  52. Pilomyxoid astrocytoma of the cerebellum with Williams syndrome: a case report Peer-reviewed

    Masashi Chonan, Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Mika Watanabe, Teiji Tominaga

    CHILDS NERVOUS SYSTEM　29　(7)　1211-1214　2013/07

    DOI： 10.1007/s00381-013-2107-7 　

    ISSN： 0256-7040

  53. Risk Assessment for Venous Thromboembolism in Patients With Neuroepithelial Tumors: Pretreatment Score to Identify High Risk Patients Peer-reviewed

    Tomohiro Kawaguchi, Toshihiro Kumabe, Masayuki Kanamori, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　53　(7)　467-473　2013/07

    DOI： 10.2176/nmc.53.467 　

    ISSN： 0470-8105

    eISSN： 1349-8029

  54. Metachronous, multicentric glioma of pilocytic astrocytoma with oligodendroglioma-like component and oligodendroglioma through distinct genetic aberrations Case report Peer-reviewed

    Atsushi Kanoke, Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Mika Watanabe, Teiji Tominaga

    JOURNAL OF NEUROSURGERY　118　(4)　854-858　2013/04

    DOI： 10.3171/2012.9.JNS112353 　

    ISSN： 0022-3085

  55. Clinicopathological analysis of nine consecutive central nervous system primitive neuroectodermal tumors in a single institute Peer-reviewed

    Misaki Aizawa-Kohama, Toshihiro Kumabe, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　30　(1)　15-27　2013/01

    DOI： 10.1007/s10014-012-0097-x 　

    ISSN： 1433-7398

  56. Subarachnoid hemorrhage in a patient with a meningioma and an unruptured aneurysm. Peer-reviewed

    Kanamori M, Tomita T, Sasaki T, Murakami K, Takahashi N, Kakehata S, Kurotaki H, Nishijima M

    Neurologia medico-chirurgica　53　(5)　343-346　2013

    DOI： 10.2176/nmc.53.343 　

    ISSN： 0470-8105

  57. Summary of 15 years experience of awake surgeries for neuroepithelial tumors in tohoku university. Peer-reviewed

    Toshihiro Kumabe, Kiyotaka Sato, Masaki Iwasaki, Ichiyo Shibahara, Tomohiro Kawaguchi, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Yukihiko Sonoda, Osamu Iizuka, Kyoko Suzuki, Ken-Ichi Nagamatsu, Shintaro Seki, Nobukazu Nakasato, Teiji Tominaga

    Neurologia medico-chirurgica　53　(7)　455-66　2013

    DOI： 10.2176/nmc.53.455 　

    ISSN： 0470-8105

    eISSN： 1349-8029

    More details Close

    We retrospectively analyzed 15 years experience of awake surgeries for neuroepithelial tumors in Tohoku University. Awake surgeries mostly for language mapping were performed for 42 of 681 newly diagnosed cases (6.2%) and 59 of 985 surgeries including for recurrence (6.0%). When the same histologies and locations as cases resected under awake condition are selected from the parent population treated by radical resection, awake surgeries were most frequently performed for 14 of 55 newly diagnosed cases (25.5%) and 14 of 62 surgeries (22.6%) with grade II gliomas. In the results, 8 of 59 surgeries (13.6%) could not achieve complete language monitoring until the final stage of tumor resection, considered as failed awake surgery. Gross total resection was accomplished in 20 of 42 newly diagnosed cases (47.6%) and 32 of 59 surgeries (54.2%). Mortality rate was 0%. Late severe deficits were observed in 2 of 42 newly diagnosed cases (4.8%) and 3 of 59 surgeries (5.1%). Negative language mapping cases did not suffer severe deficits in both early and late stages. In contrast, high incidence of severe deficits, 3 as early and 2 as late of 8 cases, were identified with failed awake surgery. The overall survival of patients treated by awake surgery compared favorably with those treated without stimulation mapping and with stimulation mapping under general anesthesia. Awake surgery may contribute to improve the outcome of gliomas near eloquent areas by maximizing the tumor resection and minimizing the surgical morbidity.

  58. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas Peer-reviewed

    Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Shunsuke Kato, Chikashi Ishioka, Teiji Tominaga

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　17　(6)　551-561　2012/12

    DOI： 10.1007/s10147-011-0323-2 　

    ISSN： 1341-9625

  59. Distinctive flow pattern of wall shear stress and oscillatory shear index: similarity and dissimilarity in ruptured and unruptured cerebral aneurysm blebs Peer-reviewed

    Tomohiro Kawaguchi, Shinjitsu Nishimura, Masayuki Kanamori, Hiroki Takazawa, Shunsuke Omodaka, Kenya Sato, Noriko Maeda, Yoko Yokoyama, Hiroshi Midorikawa, Tatsuya Sasaki, Michiharu Nishijima

    JOURNAL OF NEUROSURGERY　117　(4)　774-780　2012/10

    DOI： 10.3171/2012.7.JNS111991 　

    ISSN： 0022-3085

  60. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors Peer-reviewed

    Tomohiro Kawaguchi, Toshihiro Kumabe, Masayuki Kanamori, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    JOURNAL OF NEURO-ONCOLOGY　104　(3)　779-787　2011/09

    DOI： 10.1007/s11060-011-0544-2 　

    ISSN： 0167-594X

  61. Combination chemotherapy with ifosfamide, cisplatin, and etoposide for medulloblastoma: single-institute experience and differences in efficacy for subgroups of medulloblastoma Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Yukihiko Sonoda, Masayuki Kanamori, Yoji Yamashita, Mika Watanabe, Teiji Tominaga

    CHILDS NERVOUS SYSTEM　27　(9)　1399-1406　2011/09

    DOI： 10.1007/s00381-011-1485-y 　

    ISSN： 0256-7040

  62. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status Peer-reviewed

    Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　28　(3)　203-208　2011/07

    DOI： 10.1007/s10014-011-0050-4 　

    ISSN： 1433-7398

  63. Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases Peer-reviewed

    Tomoo Inoue, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    NEUROSURGICAL REVIEW　34　(2)　197-207　2011/04

    DOI： 10.1007/s10143-010-0306-1 　

    ISSN： 0344-5607

  64. Flow dynamics analysis in patients with a ruptured middle cerebral artery aneurysm. A case report Peer-reviewed

    Tomohiro Kawaguchi, Masayuki Kanamori, Hiroki Takazawa, Shunsuke Omodaka, Shingo Yonezawa, Noriko Maeda, Kenya Sato, Hiroshi Midorikawa, Tatsuya Sasaki, Michiharu Nishijima

    Neurological Surgery　39　(3)　281-286　2011/03/10

    ISSN： 0301-2603

  65. Early detection of venous thromboembolism in patients with neuroepithelial tumor: efficacy of screening with serum d-dimer measurements and Doppler ultrasonography Peer-reviewed

    Tomohiro Kawaguchi, Toshihiro Kumabe, Masayuki Kanamori, Taigen Nakamura, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    JOURNAL OF NEURO-ONCOLOGY　101　(3)　495-504　2011/02

    DOI： 10.1007/s11060-010-0276-8 　

    ISSN： 0167-594X

    eISSN： 1573-7373

  66. Pilocytic Astrocytoma With Histological Malignant Features Without Previous Radiation Therapy -Case Report- Peer-reviewed

    Ichiyo Shibahara, Tomohiro Kawaguchi, Masayuki Kanamori, Shingo Yonezawa, Hiroki Takazawa, Kenichiro Asano, Hiroki Ohkuma, Mitsuomi Kaimori, Tatsuya Sasaki, Michiharu Nishijima

    NEUROLOGIA MEDICO-CHIRURGICA　51　(2)　144-147　2011/02

    DOI： 10.2176/nmc.51.144 　

    ISSN： 0470-8105

  67. Ruptured peripheral aneurysms in a collateral pathway associated with stenosis of a major cerebral artery: Report of two cases. International-journal Peer-reviewed

    Shibahara I, Yonezawa S, Takazawa H, Kawaguchi T, Kanamori M, Murakami K, Midorikawa H, Sasaki T, Nishijima M

    Surgical neurology international　2　81-81　2011

    DOI： 10.4103/2152-7806.82247 　

    ISSN： 2229-5097

    More details Close

    BACKGROUND: While hemodynamic stress can result in aneurysm formation, it rarely contributes to the development of peripheral aneurysms in collateral pathways. We report two patients with ruptured distal aneurysms in a collateral pathway associated with stenosis of a major cerebral artery. CASE DESCRIPTION: A 67-year-old man presented with intracerebral hemorrhage in the right frontal lobe. Digital subtraction angiography (DSA) revealed severe stenosis of the right middle cerebral artery and two aneurysms in the collateral pathway of the right anterior cerebral artery. The ruptured aneurysm was trapped and resected; histologically, it was a true saccular aneurysm. The unruptured aneurysm was clipped and the patient was discharged without additional neurological deficits. The second patient was a 73-year-old woman with subarachnoid hemorrhage. DSA revealed three arterial dilations. On the 7(th) day of hospitalization, one of the aneurysms in a posterior inferior cerebellar artery-anterior inferior cerebellar artery anastomosis that functioned as a collateral pathway in the presence of severe basilar artery stenosis was found to be enlarged. It was treated by selective aneurysmal coil embolization with parent artery preservation. Her postoperative course was uneventful and she was discharged without any neurological deficits. CONCLUSION: We document the successful treatment of two patients with ruptured aneurysms in the peripheral portion of a collateral pathway. We discuss the histology of peripheral aneurysms and present a review of the literature.

  68. [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Teiji Tominaga

    No shinkei geka. Neurological surgery　38　(11)　997-1005　2010/11

    ISSN： 0301-2603

    More details Close

    PURPOSE: The adverse effects of combination chemotherapy of ifosfamide, cisplatin, and etoposide (ICE) were evaluated in the treatment of various intracranial brain tumors. METHODS: 108 cases were retrospectively reviewed. The histological diagnosis was newly diagnosed or recurrent germ cell tumor in 45 cases, medulloblastoma in 19, primitive neuroectodermal tumor (PNET) in 7, anaplastic ependymoma in 6, recurrent glioblastoma in 13, and others in 18 cases. Patients received 1-8 cycles of ICE chemotherapy with or without radiation therapy. The adverse effects were analyzed based on the the clinical or laboratory examinations. RESULTS: Common Terminology Criteria for Adverse Events ver. 3.0 (CTCAE v3.0) grade 4 neutropenia, anemia, and thrombocytopenia occurred in 81.4%, 14.8%, and 35.2% of patients, respectively. Non-hematological adverse effects, including infection, elevated aspartate aminotransferase (AST)/alanine aminotransferase (ALT), high or low levels of serum sodium, and seizure, occurred in 26.8%, 29.6%, 28.7%, and 11.1% of patients, respectively. One patient died of opportunistic infection with neutropenia. The proportion of ICE cycles associated with CTCAE v3.0 grade 4 neutropenia, transfusion of platelets, and elevated AST/ALT significantly decreased after enforcement of dose reduction criteria. CONCLUSION: The high rate of adverse effects requires close follow up and dose reduction.

  69. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[(18)F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new (18)F-labeled 2-nitroimidazole analog Clinical article Peer-reviewed

    Ichiyo Shibahara, Toshihiro Kumabe, Masayuki Kanamori, Ryuta Saito, Yukihiko Sonoda, Mika Watanabe, Ren Iwata, Shuichi Higano, Kentaro Takanami, Yoshihiro Takai, Teiji Tominaga

    JOURNAL OF NEUROSURGERY　113　(2)　358-368　2010/08

    DOI： 10.3171/2009.10.JNS09510 　

    ISSN： 0022-3085

  70. O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma Peer-reviewed

    Yukihiko Sonoda, Michiko Yokosawa, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Teiji Tominaga

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　15　(4)　352-358　2010/08

    DOI： 10.1007/s10147-010-0065-6 　

    ISSN： 1341-9625

  71. Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence. Peer-reviewed

    Saito R, Kumabe T, Kanamori M, Sonoda Y, Tominaga T

    Neurosurgical review　33　(2)　185-91; discussion 191　2010/04

    DOI： 10.1007/s10143-010-0243-z 　

    ISSN： 0344-5607

  72. Insulo-opercular Gliomas: Four Different Natural Progression Patterns and Implications for Surgical Indications Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　50　(4)　286-290　2010/04

    DOI： 10.2176/nmc.50.286 　

    ISSN： 0470-8105

  73. A case of symptomatic arachnoid cyst, that had been growing for 14 years, at the posterior part of the left temporal lobe Peer-reviewed

    Emiko Hori, Tomoaki Fujita, Shinjitsu Nishimura, Tomohiro Kawaguchi, Shingo Yonezawa, Masayuki Kanamori, Michiharu Nishijima

    Neurological Surgery　38　(2)　157-162　2010/02

    ISSN： 0301-2603

  74. Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis Clinical article Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Hisanori Ariga, Yoshihiro Takai, Teiji Tominaga

    JOURNAL OF NEUROSURGERY-PEDIATRICS　4　(6)　506-514　2009/12

    DOI： 10.3171/2009.7.PEDS08288 　

    ISSN： 1933-0707

  75. [Intraoperative neuronavigation system without rigid pin fixation]. Peer-reviewed

    Akamatsu Y, Kumabe T, Kanamori M, Nagamatsu K, Saito R, Sonoda Y, Sato K, Tominaga T

    No shinkei geka. Neurological surgery　37　(12)　1193-1199　2009/12

    ISSN： 0301-2603

  76. Long-term survivors of glioblastoma: clinical features and molecular analysis. International-journal Peer-reviewed

    Yukihiko Sonoda, Toshihiro Kumabe, Mika Watanabe, Yoichi Nakazato, Tomoo Inoue, Masayuki Kanamori, Teiji Tominaga

    Acta neurochirurgica　151　(11)　1349-58　2009/11

    DOI： 10.1007/s00701-009-0387-1 　

    ISSN： 0001-6268

    More details Close

    BACKGROUND: Glioblastoma is a highly lethal neoplasm with a median survival of 12-14 months; only 2-5% of patients survive >3 years. METHODS: At our institute, patients with glioblastoma are initially treated with maximum tumor resection followed by radiation and the intravenous injection of nimustine hydrochloride (ACNU). RESULTS: Using this strategy, 18 of 123 (14.6%) patients treated at our hospital survived >3 years; 7 manifested no recurrence, and the other 11 had early recurrence and received additional therapies. To identify factors associated with prolonged survival, we compared these patients with 21 short-term (<1.5 years) glioblastoma survivors. In the long-term survivors, the MGMT promoter methylation was significantly more frequent. The rate of p53 mutation was lower, and the rate of PTEN mutations and the proliferation index were slightly higher in short-term survivors. CONCLUSION: By multivariate analysis, we found that a younger age and MGMT promoter methylation were significant favorable factors in patients with glioblastoma.

  77. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients Peer-reviewed

    Yukihiko Sonoda, Toshihiro Kumabe, Taigen Nakamura, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Hiroyoshi Suzuki, Teiji Tominaga

    CANCER SCIENCE　100　(10)　1996-1998　2009/10

    DOI： 10.1111/j.1349-7006.2009.01270.x 　

    ISSN： 1347-9032

  78. Collision tumor of anaplastic oligodendroglioma and gangliocytoma: a case report Peer-reviewed

    Yoichi Takeuchi, Masayuki Kanamori, Toshihiro Kumabe, Ryuta Saito, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　26　(2)　89-93　2009/10

    DOI： 10.1007/s10014-009-0255-y 　

    ISSN： 1433-7398

  79. Differential Diagnosis Between Radiation Necrosis and Glioma Progression Using Sequential Proton Magnetic Resonance Spectroscopy and Methionine Positron Emission Tomography Peer-reviewed

    Takeshi Nakajima, Toshihiro Kumabe, Masayuki Kanamori, Ryuta Saito, Manabu Tashiro, Mika Watanabe, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　49　(9)　394-401　2009/09

    DOI： 10.2176/nmc.49.394 　

    ISSN： 0470-8105

  80. Magnetic resonance imaging for preoperative identification of the lenticulostriate arteries in insular glioma surgery Technical note Peer-reviewed

    Ryuta Saito, Toshihiro Kumabe, Takashi Inoue, Shihomi Takada, Yoji Yamashita, Masayuki Kanamori, Yukihiko Sonoda, Teiji Tominaga

    JOURNAL OF NEUROSURGERY　111　(2)　278-281　2009/08

    DOI： 10.3171/2008.11.JNS08858 　

    ISSN： 0022-3085

  81. Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Yukihiko Sonoda, Yoshikazu Nishino, Mika Watanabe, Teiji Tominaga

    JOURNAL OF NEURO-ONCOLOGY　93　(2)　219-228　2009/06

    DOI： 10.1007/s11060-008-9762-7 　

    ISSN： 0167-594X

  82. [A case report of cerebellar pleomorphic xanthoastrocytoma]. Peer-reviewed

    Mano Y, Kanamori M, Sonoda Y, Kumabe T, Watanabe M, Tominaga T

    No shinkei geka. Neurological surgery　37　(6)　586-590　2009/06

    ISSN： 0301-2603

  83. Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma Peer-reviewed

    Ichiyo Shibahara, Masayuki Kanamori, Toshihiro Kumabe, Hidenori Endo, Yukihiko Sonoda, Yoshikazu Ogawa, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　26　(1)　1-5　2009/04

    DOI： 10.1007/s10014-008-0243-7 　

    ISSN： 1433-7398

  84. Application of high-definition flexible neuroendoscopic system to the treatment of primary pineal malignant B-cell lymphoma Peer-reviewed

    Hidenori Endo, Miki Fujimura, Toshihiro Kumabe, Masayuki Kanamori, Mika Watanabe, Teiji Tominaga

    SURGICAL NEUROLOGY　71　(3)　344-348　2009/03

    DOI： 10.1016/j.surneu.2007.08.029 　

    ISSN： 0090-3019

  85. [Primary yolk sac tumor in the cerebellar vermis. Case report]. Peer-reviewed

    Nakamura T, Kanamori M, Sonoda Y, Watanabe M, Kumabe T, Tominaga T

    No shinkei geka. Neurological surgery　37　(2)　173-177　2009/02

    ISSN： 0301-2603

  86. Papillary tumor of the pineal region: a case report Peer-reviewed

    Tomoo Inoue, Toshihiro Kumabe, Masayuki Kanamori, Yukihiko Sonoda, Mika Watanabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　25　(2)　85-90　2008/11

    DOI： 10.1007/s10014-008-0231-y 　

    ISSN： 1433-7398

  87. [Clinical application of pulsed laser-induced liquid jet: preliminary report in glioma surgery]. Peer-reviewed

    Nakagawa A, Kumabe T, Kanamori M, Saito R, Hirano T, Takayama K, Tominaga T

    No shinkei geka. Neurological surgery　36　(11)　1005-1010　2008/11

    ISSN： 0301-2603

  88. Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region? Peer-reviewed

    Kanamori M, Kumabe T, Tominaga T

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia　15　(9)　978-987　2008/09

    DOI： 10.1016/j.jocn.2007.08.004 　

    ISSN： 0967-5868

  89. Germ cell tumors in the basal ganglia: problems of early diagnosis and treatment Peer-reviewed

    Yukihiko Sonoda, Toshihiro Kumabe, Shin-Ichiro Sugiyama, Masayuki Kanamori, Yoji Yamashita, Ryuta Saito, Hisanori Ariga, Yoshihiro Takai, Teiji Tominaga

    JOURNAL OF NEUROSURGERY-PEDIATRICS　2　(2)　118-124　2008/08

    DOI： 10.3171/PED/2008/2/8/118 　

    ISSN： 1933-0707

  90. [Clinical features and significance of negative motor response in intraoperative language mapping during awake craniotomy]. Peer-reviewed

    Nagamatsu K, Kumabe T, Suzuki K, Nakasato N, Sato K, Iizuka O, Kanamori M, Sonoda Y, Tominaga T

    No shinkei geka. Neurological surgery　36　(8)　693-700　2008/08

    ISSN： 0301-2603

  91. [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report]. Peer-reviewed

    Inoue T, Kanamori M, Sonoda Y, Watanabe M, Sasajima T, Kamisato N, Kumabe T, Tominaga T

    No shinkei geka. Neurological surgery　36　(8)　709-715　2008/08

    ISSN： 0301-2603

  92. [Multiple intracerebral enhanced lesions strongly suspected to be microsporidiosis. A case report]. Peer-reviewed

    Okuyama H, Kanamori M, Watanabe M, Kumabe T, Tominaga T

    No shinkei geka. Neurological surgery　36　(7)　645-650　2008/07

    ISSN： 0301-2603

  93. Medulloblastoma demonstrating multipotent differentiation: case report Peer-reviewed

    Hiroyuki Sakata, Masayuki Kanamori, Mika Watanabe, Toshihiro Kumabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　25　(1)　39-43　2008/04

    DOI： 10.1007/s10014-007-0228-y 　

    ISSN： 1433-7398

  94. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene Peer-reviewed

    Tatsuro Fukuhara, Yasuo Saijo, Tomohiro Sakakibara, Akira Inoue, Naoto Morikawa, Masayuki Kanamori, Ichiro Nakashima, Toshihiro Nukiwa

    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　214　(4)　359-363　2008/04

    DOI： 10.1620/tjem.214.359 　

    ISSN： 0040-8727

    eISSN： 1349-3329

  95. Spinal granulocytic sarcoma manifesting as radiculopathy in a nonleukemic patient Peer-reviewed

    Tomoo Inoue, Toshiyuki Takahashi, Hiroaki Shimizu, Masayuki Kanamori, Toshihiro Kumabe, Mika Watanabe, Teiji Tominaga

    NEUROLOGIA MEDICO-CHIRURGICA　48　(3)　131-136　2008/03

    DOI： 10.2176/nmc.48.131 　

    ISSN： 0470-8105

  96. Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma - Case report Peer-reviewed

    Masayuki Kanamori, Toshihiro Kumabe, Mika Watanabe, Teji Tominaga

    JOURNAL OF NEUROSURGERY　107　(1)　185-189　2007/07

    DOI： 10.3171/JNS-07/07/0185 　

    ISSN： 0022-3085

  97. Contribution of Notch signaling activation to human glioblastoma multiforme Peer-reviewed

    Masayuki Kanamori, Tomohiro Kawaguchi, Janice M. Nigro, Burt G. Feuerstein, Mitchel S. Berger, Lucio Miele, Russell O. Pieper

    JOURNAL OF NEUROSURGERY　106　(3)　417-427　2007/03

    DOI： 10.3171/jns.2007.106.3.417 　

    ISSN： 0022-3085

  98. Intracranial microenvironment reveals independent opposing functions of host alpha V beta 3 expression on glioma growth and angiogenesis Peer-reviewed

    Masayuki Kanamori, Tomohiro Kawaguchi, Mitchel S. Berger, Russell O. Pieper

    JOURNAL OF BIOLOGICAL CHEMISTRY　281　(48)　37256-37264　2006/12

    DOI： 10.1074/jbc.M605344200 　

    ISSN： 0021-9258

  99. The PTEN/Akt pathway dictates the direct alpha(v)beta(3)-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo Peer-reviewed

    Tomohiro Kawaguchi, Yoji Yamashita, Masayuki Kanamori, Raelene Endersby, Krystof S. Bankiewicz, Suzanne J. Baker, Gabriele Bergers, Russell O. Pieper

    CANCER RESEARCH　66　(23)　11331-11340　2006/12

    DOI： 10.1158/0008-5472.CAN-06-1540 　

    ISSN： 0008-5472

  100. Integrin beta 3 overexpression suppresses tumor growth in a human model of gliomagenesis: Implications for the role of beta 3 overexpression in glioblastoma multiforme Peer-reviewed

    M Kanamori, Vanden Berg, SR, G Bergers, MS Berger, RO Pieper

    CANCER RESEARCH　64　(8)　2751-2758　2004/04

    DOI： 10.1158/0008-5472.CAN-03-3354 　

    ISSN： 0008-5472

  101. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis Peer-reviewed

    Y Sonoda, M Kanamori, DF Deen, SY Cheng, MS Berger, RO Pieper

    CANCER RESEARCH　63　(8)　1962-1968　2003/04

    ISSN： 0008-5472

  102. Tl-201-SPECT, H-1-MRS, and MIB-1 labeling index of central neurocytomas: Three case reports Peer-reviewed

    M Kanamori, T Kumabe, H Shimizu, T Yoshimoto

    ACTA NEUROCHIRURGICA　144　(2)　157-163　2002

    DOI： 10.1007/s007010200019 　

    ISSN： 0001-6268

  103. Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene Peer-reviewed

    M Kanamori, H Kon, T Nobukuni, S Nomura, K Sugano, S Mashiyama, T Kumabe, T Yoshimoto, M Meuth, T Sekiya, Y Murakami

    ONCOGENE　19　(12)　1564-1571　2000/03

    DOI： 10.1038/sj.onc.1203454 　

    ISSN： 0950-9232

  104. [A slowly progressed case of brain metastasis and meningeal carcinomatosis from lung cancer] Peer-reviewed

    Kitahara M, Seki K, Kanamori M

    No Shinkei Geka.　25　(12)　1131-1135　1997/12

  105. [A case of chronic expanding epidural hematoma] Peer-reviewed

    Kanamori M, Seki K, Kitahara M

    No Shinkei Geka.　25　(12)　1137-1142　1997/12

Show all ︎Show first 5

Misc. 1

  1. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status

    Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga

    BRAIN TUMOR PATHOLOGY　28　(3)　203-208　2011/07

    DOI： 10.1007/s10014-011-0050-4 　

    ISSN： 1433-7398

Books and Other Publications 2

  1. プライム脳神経外科

    木内博之, 斎藤延人

    三輪書店　2018/04

  2. 脳腫瘍学

    金森 政之

    日本臨床社　2016/09

Presentations 94

  1. 第四脳室上衣腫の摘出度と機能温存・腫瘍制御

    金森政之, 斎藤竜太, 園田順彦, 隈部俊宏, 冨永悌二

    第28回脳神経外科手術と機器学会　2019/04/12

  2. 高齢者膠芽腫治療の現状と現在の治療の問題点 Invited

    金森政之, 斎藤竜太, 冨永悌二

    第32回日本老年脳神経外科学会　2019/03/29

  3. 髄液細胞診陽性ジャーミノーマに対する全脳全脊髄照射の意義

    金森政之, 高見浩数, 市村幸一, 冨永悌二, 西川亮

    第36回日本脳腫瘍学会　2018/12/02

  4. 右側頭葉退形成性髄膜腫の1例

    金森政之, 渡辺みか, 斎藤竜太, 冨永悌二

    第25回東北神経病理研究会　2018/11/10

  5. 初期治療後１０年以上経過した頭蓋内胚腫の機能予後

    金森政之, 斎藤竜太, 飯塚統, 西尾慶之, 麦倉俊司, 佐久間篤, 上埜高志, 園田順彦, 隈部俊宏, 鈴木匡子, 冨永悌二

    日本脳神経外科学会 第77回学術総会　2018/10/12

  6. Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia

    Masayuki Kanamori, Takumi Kajitani, Ryuta Saito, Yuko Watanabe, Hiroyoshi Suzuki, Mika Watanabe, Shigeo Kure, Teiji Tominaga

    2018/09/25

  7. 頭蓋内胚細胞腫のsalvage surgeryの適応

    金森政之, 斎藤竜太, 渡辺みか, 小川欣一, 園田順彦, 隈部俊宏, 冨永悌二

    第23回日本脳腫瘍の外科学会　2018/09/14

  8. 錐体路近傍神経膠腫摘出における白質錐体路マッピング・モニタリングの意義

    金森政之, 斎藤竜太, 浅黄優, 長南雅志, 明石敏明, 中里信和, 冨永悌二

    第27回脳神経外科手術と機器学会　2018/04/14

  9. Bifocal lesion・尿崩症・腫瘍マーカー陰性症例における組織診断の必要性

    金森政之, 高見浩数, 斎藤竜太, 冨永悌二, 市村幸一, 西川亮

    第35回日本脳腫瘍病理学会　2017/11/26

  10. Necessity for Histological Verification of Germinoma with Bifocal Lesion, Diabetes Insipidus and Normal Levels of Tumor Markers.

    Masayuki Kanamori, Hirokazu Takami, Ryuta Saito, Teiji Tominaga, Kochi Ichimura, Ryo Nishikawa

    14th meeting of the Asian society of Neurooncology　2017/10/29

  11. 再発胚腫に対する全脳全脊髄照射の長期成績

    金森政之, 斎藤竜太, 長南雅志, 園田順彦, 隈部俊宏, 冨永悌二

    日本脳神経外科学会 第76回学術総会　2017/10/12

  12. BRAF遺伝子変異を有する星細胞腫の1例

    金森政之, 鈴木博義, 渡辺みか, 長南雅志, 斎藤竜太, 冨永悌二

    第24回東北神経病理研究会　2017/10/07

  13. Optic hypothalamic pilocytic astrocytomaの外科

    金森政之, 齋藤竜太, 藤村幹, 園田順彦, 隈部俊宏, 冨永悌二

    第22回日本脳腫瘍の外科学会　2017/08/30

  14. 術中迅速診断へのmass spectroscopyの応用

    金森政之, 前川正充, 柴原一陽, 斎藤竜太, 園田順彦, 渡辺みか, 冨永悌二

    第18回日本分子脳神経外科学会　2017/08/26

  15. Necessity for craniospinal irradiation of germinoma with positive cytology. International-presentation

    Kanamori M, Takami K, Saito R, Ichimura K, Tominaga T, Nishikawa R

    5th international CNS germ cell tumor sympoium　2017/06/09

  16. Necessity for Histological Verification of Germinoma with Bifocal Lesion, Diabetes Insipidus and Normal Levels of Tumor Markers. International-presentation

    Kanamori M, Takami K, Saito R, Ichimura K, Tominaga T, Nishikawa R

    5th international CNS germ cell tumor sympoium　2017/06/08

  17. 術中迅速診断へのmass spectroscopyの応用

    金森政之, 前川正充, 柴原一陽, 斎藤竜太, 園田順彦, 渡辺みか, 冨永悌二

    第35回日本脳腫瘍病理学会　2017/05/20

  18. Optic hypothalamic pilocytic astrocytomaの外科

    金森政之, 齋藤竜太, 藤村幹, 園田順彦, 隈部俊宏, 冨永悌二

    第26回脳神経外科手術と機器学会　2017/04/14

  19. リキッドバイオプシー

    金森政之, 齋藤竜太, 冨永悌二

    第50回東北脳腫瘍研究会　2017/03/25

  20. IDH遺伝子変異・第1染色体短腕／第19染色体長腕共欠失を有する乏突起膠腫の長期予後

    金森政之, 斎藤竜太, 渡辺みか, 山下洋二, 園田順彦, 隈部俊宏, 冨永悌二

    第34回日本脳腫瘍学会学術集会　2016/12/05

  21. 初期治療から5年以上経過した 頭蓋内胚腫患者の 就学・就業に関する検討

    金森 政之, 斎藤 竜太, 園田 順彦, 隈部 俊宏, 冨永 悌二

    日本脳神経外科学会 第75回学術総会　2016/10/01

  22. 頭蓋内胚細胞腫瘍におけるNeoadjuvant therapy後のsalvage surgeryの意義

    金森政之, 齋藤竜太, 渡辺みか, 園田順彦, 隈部俊宏, 冨永悌

    第２１回日本脳腫瘍の外科学会　2016/09/10

  23. 頭蓋内胚腫における脳室壁造影所見の臨床的意義

    金森 政之, 斎藤 竜太, 園田 順彦, 隈部 俊宏, 冨永 悌二

    第53回日本脳神経外科学会東北支部会　2016/09/03

  24. 頭蓋内胚細胞腫瘍の髄液細胞診と画像所見

    金森政之, 斎藤竜太, 渡辺みか, 園田順彦, 隈部俊宏, 冨永悌二

    第34回日本脳腫瘍病理学会　2016/05/28

  25. 膠芽腫における播種病変

    金森政之, 斎藤竜太, 冨永悌二

    第49回東北脳腫瘍研究会　2016/04/02

  26. 急性リンパ性白血病寛解中に膠芽腫を発症した2例

    金森政之, 斎藤竜太, 渡辺裕子, 新妻秀剛, 笹原洋二, 渡辺みか, 呉繁夫, 冨永悌二

    第３８回東北がん小児腫瘍研究会　2016/03/19

  27. 退形成性神経膠腫におけるNRF2経路活性化と予後に関する検討

    金森政之, 園田順彦, 比嘉武, 村上昌平, 柴原一陽, 斎藤竜太, 山下洋二, 隈部俊宏, 山本雅之, 本橋ほづみ, 冨永悌二

    第33回日本脳腫瘍学会　2015/12

  28. ベバシズマブ投与による悪性神経膠腫での腫瘍内出血に関する検討

    金森政之, 栗原紀子, 上之原広司, 冨永悌二

    日本脳神経外科学会 第74回学術総会　2015/10/15

  29. 再発頸静脈孔神経鞘腫に対する外科治療

    金森政之, 橋本省, 上之原広司, 冨永悌二

    第20回日本脳腫瘍の外科学会　2015/09/25

  30. テモゾロミド投与におけるＢ型肝炎ウイルス-DNA測定の意義

    金森政之, 齋藤竜太, 上之原広司, 冨永悌二

    第52回日本脳神経外科学会東北支部会　2015/09/05

  31. 退形成性神経膠腫におけるNRF2経路活性化と予後に関する検討

    金森政之, 園田順彦, 比嘉武, 村上昌平, 柴原一陽, 斎藤竜太, 山下洋二, 隈部俊宏, 山本雅之, 本橋ほづみ, 冨永悌二

    第16回日本分子脳神経外科学会　2015/08/29

  32. 退形成性神経膠腫における IDH1 R132Hタンパク発現と 予後に関する検討

    金森 政之

    金森政之、 鈴木博義、 渡邊みか、 柴原一陽、斎藤竜太、園田順彦、隈部俊宏、冨永悌二　2015/05/29

  33. Differences of histological and clinical characteristics in the teratoma during the treatment for intracranial germ cell tumors International-presentation

    Masayuki Kanamori, Toshihiro Kumabe, Mika Watanabe, Ryuta Saito, Yoji Yamashita, Yukihiko Sonoda, Teiji Tominaga

    4th international symposium on intracranial germ cell tumors　2015/04

  34. Optic pathway/hypothalamic astrocytoma -自然歴・治療反応性

    金森政之, 斎藤竜太, 山下洋二, 園田順彦, 隈部俊宏, 冨永悌二

    第48回東北脳腫瘍研究会　2015/03/21

  35. IDH1/2遺伝子変異検出による術中遺伝子診断の試み

    金森政之, 渡辺みか, 菊池敦生, 柴原一陽, 斎藤竜太, 山下洋二, 園田順彦, 呉繁夫, 隈部俊宏, 冨永悌二

    第32回日本脳腫瘍学会　2014/11/30

  36. IDH1/2遺伝子変異検出による術中遺伝子診断の試み

    金森政之, 渡辺みか, 菊池敦生, 柴原一陽, 斎藤竜太, 山下洋二, 園田順彦, 呉繁夫, 隈部俊宏, 冨永悌二

    日本脳神経外科学会 第73回学術総会　2014/10/10

  37. IDH1/2遺伝子変異検出による術中遺伝子診断の試み

    金森政之, 渡辺みか, 菊池敦生, 柴原一陽, 斎藤竜太, 山下洋二, 園田順彦, 呉繁夫, 隈部俊宏, 冨永悌二

    第32回日本脳腫瘍病理学会　2014/05/23

  38. 金森政之、斎藤竜太、山下洋二、園田順彦、隈部俊宏、冨永悌二

    2013/10/16

  39. 頭蓋内奇形腫の病理像

    金森政之, 隈部俊宏, 斎藤竜太, 山下洋二, 園田順彦, 渡辺みか, 冨永悌二

    第30回日本脳腫瘍病理学会　2013/05/25

  40. 成熟奇形腫と診断され摘出術単独治療21年後に局所・播種再発をきたした松果体部胚細胞系腫瘍の1例

    金森政之, 隈部俊宏, 斎藤竜太, 渡辺みか, 冨永悌二

    第50回日本脳神経外科学会東北支部会　2013/03/30

  41. 初発奇形腫と放射線化学療法後に摘出された奇形腫の臨床像の相違

    金森政之, 隈部俊宏, 斎藤竜太, 山下洋二, 園田順彦, 渡辺みか, 冨永悌二

    第30回日本脳脳腫瘍学会　2012/12

  42. 右側頭葉に発生した乏突起肉腫の1例

    金森政之, 渡辺みか, 内田浩喜, 斎藤竜太, 隈部俊宏, 冨永悌二

    第19回東北神経病研究会　2012/11/17

  43. 初発奇形腫と放射線化学療法後に摘出された奇形腫の臨床像の相違

    金森政之, 隈部俊宏, 斎藤竜太, 山下洋二, 園田順彦, 渡辺みか, 冨永悌二

    第71回日本脳神経外科学会総会　2012/10

  44. 帯状回神経膠腫摘出術後における補足運動野症候群

    金森政之, 隈部俊宏, 斎藤竜太, 山下洋二, 園田順彦, 冨永悌二

    第13回日本脳腫瘍の外科学会　2012/09/08

  45. 膠肉腫の臨床病理像

    金森政之, 渡辺みか, 柴原一陽, 斎藤竜太, 山下洋二, 園田順彦, 隈部俊宏, 冨永悌二

    第29回日本脳腫瘍病理学会　2012/05/25

  46. テモゾロミド導入後の高齢者膠芽腫の治療成績

    園田順彦, 柴原一陽, 齋藤竜太, 金森政之, 山下洋二, 隈部俊宏, 上之原広司, 冨永悌二

    日本脳腫瘍学会　2011/11/27

  47. 乏突起細胞腫群におけるIDH遺伝子変異、および第1染色体短腕・第19染色体長腕欠失の有無とMRI所見

    金森政之, 園田順彦, 柴原一陽, 斎藤竜太, 山下洋二, 隈部俊宏, 冨永悌二

    日本脳腫瘍学会　2011/11/27

  48. 6) 神経膠腫患者における静脈血栓塞栓症発症危険因子の検討と患者層別化の試み

    川口奉洋, 隈部俊宏, 園田順彦, 山下洋二, 金森政之, 斎藤竜太, 冨永悌二

    日本脳腫瘍学会　2011/11/27

  49. Analysis of recurrence pattern and its associated factors in primary glioblastoma

    柴原一陽, 園田順彦, 隈部俊宏, 齋藤竜太, 金森政之, 山下洋二, 加藤俊介, 石岡千加史, 渡部みか, 冨永悌二

    日本脳腫瘍学会　2011/11/27

  50. MRI モニタリング下ニトロソウレア剤局所投薬による悪性神経膠腫新規治療法の開発

    齋藤竜太, 園田順彦, 山下洋二, 金森政之, 永松謙一, 隈部俊宏, 冨永悌二

    日本癌治療学会　2011/10/27

  51. テモゾロミド導入後の高齢者膠芽腫の治療成績

    園田順彦, 柴原一陽, 齋藤竜太, 金森政之, 山下洋二, 隈部俊宏, 上之原広司, 冨永悌二

    日本脳神経外科学会総会　2011/10/12

  52. 乏突起細胞腫群におけるIDH遺伝子変異、および第1染色体短腕・第19染色体長腕欠失の有無とMRI所見

    金森政之, 園田順彦, 柴原一陽, 斎藤竜太, 山下洋二, 隈部俊宏, 冨永悌二

    日本脳神経外科学会総会　2011/10/12

  53. 悪性神経膠腫に対するConvection-enhanced delivery：現状と展望

    齋藤竜太, 隈部俊宏, 金森政之, 山下洋二, 園田順彦, 高橋昭喜, 冨永悌二

    外科　2011/10/12

  54. Analysis of recurrence pattern and its associated factors in primary glioblastoma

    柴原一陽, 園田順彦, 隈部俊宏, 齋藤竜太, 金森政之, 山下洋二, 加藤俊介, 石岡千加史, 渡部みか, 冨永悌二

    日本　2011/10/12

  55. MRI Guided Convection-Enhanced Delivery of Nimustine Hydrochloride Against Recurrent Glioma Affecting Brain Stem International-presentation

    Ryuta Saito, Yukihiko Sonoda, Yoji Yamashita, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga

    2) 8th Annual World Congress of IBMISPS on Brain, Spinal Cord Mapping and Image Guided Therapy　2011/06/08

  56. 乏突起細胞腫群におけるIDH遺伝子変異、および第1染色体短腕・第19染色体長腕欠失の有無とMRI所見

    金森政之, 園田順彦, 柴原一陽, 斎藤竜太, 山下洋二, 隈部俊宏, 冨永悌二

    日本脳腫瘍病理学会　2011/05/20

  57. テモゾロミド導入後の高齢者膠芽腫の治療成績

    園田順彦, 柴原一陽, 齋藤竜太, 金森政之, 山下洋二, 隈部俊宏, 渡辺みか, 中里洋一, 冨永悌二

    日本脳腫瘍病理学会　2011/05/20

  58. Infratentorial oligodendroglial tumor 4例の臨床病理学的検討

    齋藤竜太, 隈部俊宏, 柴原一陽, 大沢伸一郎, 金森政之, 山下洋二, 園田順彦, 渡辺みか, 冨永悌二

    日本脳腫瘍病理学会　2011/05/20

  59. Clinical and molecular analysis of high grade glioma based on IDH gene status

    柴原一陽, 園田順彦, 隈部俊宏, 齋藤竜太, 金森政之, 山下洋二, 石岡千加史, 渡部みか, 冨永悌二

    日本脳腫瘍病理学会　2011/05/20

  60. 小児神経膠腫の治療コンセンサス

    園田順彦, 隈部俊宏, 齋藤竜太, 金森政之, 山下洋二, 冨永悌二

    日本脳神経外科コングレス　2011/05/06

  61. diffuse astrocytomaの長期治療成績

    金森政之, 渡辺みか, 園田順彦, 隈部俊宏, 冨永悌二

    日本脳腫瘍学会　2007/12/09

  62. 悪性神経膠腫に発生した肺塞栓症

    山下洋二, 川口奉洋, 金森政之, 園田順彦, 隈部俊宏, 冨永悌二

    日本　2007/12/09

  63. 再発germinomaに対する治療

    隈部俊宏, 金森政之, 園田順彦, 高井良尋, 冨永悌二

    日本　2007/12/09

  64. 膠芽腫長期生存例の解析

    園田順彦, 渡辺みか, 井上智夫, 金森政之, 隈部俊宏

    日本　2007/12/09

  65. anaplastic ependymomaの治療成績

    斎藤竜太, 隈部俊宏, 金森政之, 園田順彦, 冨永悌二

    日本　2007/12/09

  66. Contribution of Notch signaling activation to human glioblastoma multiforme . International-presentation

    Kanamori M, Kawaguchi T, Nigro J, Burt Feuerstein, B Mitchel S. Berger MS, Lucio Miele L, Kumabe T, Tominaga T, Russell O. Pieper RO

    5th meeting of the Asian Society for Neuro-Oncology　2007/11/02

  67. Minimum ADC is significantly correlated with cellurarity in medulloblastomas International-presentation

    Yamashita Y, Kumabe T, Sonoda Y, Kanamori M, Higano S, Watanabe M, Tominaga T

    5th meeting of the Asian Society for Neuro-Oncology　2007/11/02

  68. diffuse astrocytomaの長期治療成績

    金森政之, 渡辺みか, 園田順彦, 隈部俊宏, 冨永悌二

    日本脳神経外科学会総会　2007/10/04

  69. GLIOBLASTOMAの長期生存例の検討

    園田順彦, 井上智夫, 渡辺みか, 金森政之, 隈部俊宏, 冨永悌二

    日本脳神経外科学会総会　2007/10/03

  70. 神経膠腫症18例の検討

    井上智夫, 隈部俊宏, 金森政之, 渡辺みか, 園田順彦, 冨永悌二

    日本脳神経外科学会総会　2007/10/03

  71. 脳神経外科における細血管温存下切開デバイスの開発

    冨永悌二, 中川敦寛, 隈部俊宏, 金森政之, 斎藤竜太, 佐々木健吾, 平野孝幸, 高山和喜

    日本脳神経外科　2007/10/03

  72. clinical features of malignant glioneuronal tumors

    佐藤健一, 金森政之, 渡辺みか, 隈部俊宏, 冨永悌二

    日本　2007/10/03

  73. 小児脳腫瘍の休眠状態の存在

    永松謙一, 金森政之, 斎藤竜太, 山下洋二, 井上智夫, 隈部俊宏, 冨永悌二

    日本　2007/10/03

  74. Notch経路の膠芽腫の進展に果たす役割に関する検討

    金森政之, 川口奉洋, Nigro J, Burt Feuerstein, B Mitchel S. Berger MS, Lucio Miele L, 隈部俊宏, 冨永悌二, Pieper RO

    日本分子脳神経外科学会　2007/09/02

  75. 5ALAによる術中蛍光診断と病理組織像の検討

    金森政之, 斎藤竜太, 渡辺みか, 隈部俊宏, 冨永悌二

    脳神経外科手術と機器学会　2007/04/13

  76. メチオニンPETが病変の活動性評価に有用であった一例

    金森政之, 隈部俊宏, 田代学, 渡辺みか, 中里洋一, 冨永悌二

    日本脳神経外科学会東北地方会　2007/03/20

  77. 初期治療8年後に小脳虫部に膠芽腫を形成した神経膠腫症の1症例

    井上智夫, 金森政之, 隈部俊宏, 渡辺みか, 笹嶋寿郎, 神里信夫, 冨永悌二

    日本脳神経外科学会東北地方会　2007/03/20

  78. 11C-methinine PETが病変の活動性評価に有用であった1例

    金森政之, 隈部俊宏, 渡辺みか, 中里洋一, 田代学, 伊藤正敏, 冨永悌二

    日本脳神経外科学会東北地方会　2007/03/06

  79. 初期治療9年後に小脳虫部に膠芽腫を形成した神経膠腫症の1症例

    井上智夫, 金森政之, 園田順彦, 渡辺みか, 笹嶋寿郎, 神里信夫, 隈部俊宏, 冨永悌二

    日本脳神経外科学会東北地方会　2007/03/06

  80. 5-ALAによる術中診断と病理組織像の検討

    金森政之, 斎藤竜太, 渡辺みか, 隈部俊宏, 冨永悌二

    日本光線力学研究会　2007/02/24

  81. 5ALAによる術中蛍光診断と病理組織像の検討

    金森政之, 斎藤竜太, 渡辺みか, 隈部俊宏, 冨永悌二

    日本光線力学研究会　2007/02/17

  82. 神経系への分化を示す小型異型細胞群を含有した膠芽腫の一例

    佐藤健一, 金森政之, 渡辺みか, 隈部俊宏, 冨永悌二

    東北神経病理研究会　2006/11/25

  83. 乏突起膠腫における予後規定因子に関する検討

    金森政之, 渡辺みか, 隈部俊宏, 冨永悌二

    日本脳神経外科学会総会　2006/10/18

  84. 脳腫瘍診断における見かけ上の拡散係数測定の有用性

    山下洋二, 隈部俊宏, 金森政之, 菊池登志雄, 富永悌二

    日本脳神経外科学会　2006/10/18

  85. Tumstatinによるインテグリン依存性腫瘍増殖抑制効果におけるPTEN/AKT経路の役割について

    川口奉洋, 山下洋二, 金森政之, 隈部俊宏, 富永悌二, Krystof Bankiewicz, Gabriele Berger, Russel O Pieper

    日本脳神経外科　2006/10/18

  86. 微笑血管温存を目的とした新規脳腫瘍切開デバイスの開発

    中川淳寛, 隈部俊宏, 金森政之, 斉藤竜太, 平野孝之, 冨永悌二, 高山和喜

    日本脳神経外科学会総会　2006/10/18

  87. 乏突起膠腫における予後規定因子に関する検討

    金森政之, 渡辺みか, 隈部俊宏, 冨永悌二

    日本脳腫瘍学会　2006/10/01

  88. ACNUを基本化学療法剤とした膠芽腫の治療成績

    隈部俊宏, 金森政之, 富永悌二

    日本脳神経外科学会　2006/10/01

  89. CED法を用いたACNU脳内局所投与の安全性と効果

    山下洋二, 杉山慎一郎, 斎藤竜太, 菊池登志雄, 金森政之, 隈部俊宏, 冨永悌二

    日本脳腫瘍学会　2006/10/01

  90. 基底核胚細胞腫瘍の臨床的特徴

    杉山慎一郎, 山下洋二, 金森政之, 斎藤竜太, 隈部俊宏, 冨永悌二

    日本　2006/10/01

  91. 髄芽腫における見かけ上の拡散係数測定の意義

    山下洋二, 隈部俊宏, 金森政之, 冨永悌二, 日向野修一, 渡辺みか

    日本脳腫瘍病理学会　2006/06/30

  92. Preradiation chemotherapy for malignant brain tumor patients youger than 3 years old: experience with 10 consecutive cases International-presentation

    Nizuma K, Kumabe T, Saito R, Kanamori M, Shirane R, Tominaga T

    12TH INTERNATIONAL SYMPOSIUM ON PEDIATRIC NEURO-ONCOLOGY　2006/06/07

  93. Clinical characteristics of germ cell tumors originating in the basal ganglia International-presentation

    Sugiyama S, Yamashita Y, Kanamori M, Saito R, Kumabe T, Tominaga T

    12TH INTERNATIONAL SYMPOSIUM ON PEDIATRIC NEURO-ONCOLOGY　2006/06/07

  94. 基底核

    杉山慎一郎, 斎藤竜太, 金森政之, 山下洋二, 隈部俊宏, 冨永悌二

    北日本脳神経外科連合学術集会　2006/05/30

Show all Show first 5

Research Projects 9

  1. 網羅的代謝産物解析による星細胞腫の悪性転化機序解明と早期診断への応用 Competitive

    金森 政之

    Offer Organization: 文部科学省

    System: 科学研究費助成事業 基盤研究C

    2019/04 - 2021/03

  2. 放射線認知障害：Advanced MR による発症機構解明と動物モデルによる検証 Competitive

    Mugikura Shunji

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Scientific Research (B)

    2017 - 2021

  3. 悪性神経膠腫での非侵襲で繰り返し評価可能なバイオマーカーの開発 Competitive

    Masayuki Kanamori

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Scientific Research (C)

    2016 - 2018

    More details Close

    脳腫瘍の中で代表的な疾患である神経膠腫の分子診断、治療反応性予測を1H-MRSで予測することを目的に、前方視的にLCModelによる1H-MRSで腫瘍内の代謝産物を測定し、検討を進めている。

  4. 悪性神経膠腫の予後とKEAP1-NRF2ストレス応答系の関連についての検討 Competitive

    Toshihiro Kumabe

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Scientific Research (C)

    2012 - 2012

    More details Close

    悪性神経膠腫は1年生存率が50%前後と非常に予後不良な疾患である。これらの理由として放射線化学療法抵抗性が挙げられ、治療成績向上のためにはこれらの機序を明らかにする必要がある。近年、肺癌の治療抵抗性において生体ストレス応答系が重要な役割を果たすことが報告された。この応答系では転写因子NRF2が遺伝子変異により恒常的に活性化し、治療抵抗性を獲得していることが明らかになった。このような背景から悪性神経膠腫における転写因子NRF2活性と予後につき検討し、NRF2の活性上昇例では予後不良であることが判明した。本研究では悪性神経膠腫における治療抵抗性の獲得においてNRF2の果たす役割・調節機序を明らかにすることを目的として研究を行った。まず予後が比較的良好な神経膠腫症例で頻繁に認められるIDH1遺伝子の変異とストレス応答系の相互作用を検討するために神経膠腫細胞株に変異IDH1遺伝子を強制発現させた細胞株を樹立した。これを用いて転写因子NRF2の標的遺伝子の発現を定量的Realtime PCRで検討した。結果IDH1遺伝子変異の存在下ではこれらのストレス応答は反応が低下していることが判明した。さらに機序を明らかにするためにクロマチン沈降法による検討をおこないNRF2と標的遺伝子のプロモーター領域の相互作用を検討し、IDH1遺伝子変異と発現低下の原因の一つがプロモーター領域のメチル化によることが判明した。

  5. 膠芽腫に対する、薬剤耐性克服を目的としたCED法と全身投与の併用療法 Competitive

    Yukihiko Sonoda

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Scientific Research (B)

    2008 - 2010

    More details Close

    膠芽腫の化学療法剤として汎用されているのはニトロソウレアあるいは、テモゾロミドといったアルキル化剤であり、その薬剤耐性にはMGMTというDNA 修復酵素が強く関与している。この耐性を克服するには高濃度の薬剤を投与しMGMTを枯渇させることが必要である。本研究ではこれを克服するため、ACNUのCED法による局所投与とTMZの全身投与をおこなった。結果として、両者の併用療法は単剤投与に比較し有意にラット脳腫瘍モデルで生存期間の延長を認めた。引き続きカニクイザル脳内に同様の治療法をおこないその安全性を確認し、同時に脳内への良好な薬剤分布を確認した。

  6. 悪性脳腫瘍における循環腫瘍由来核酸解析の有用性に関する検討 Competitive

    Masayuki Kanamori

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Young Scientists (B)

    2008 - 2009

    More details Close

    血清または血漿に含まれる腫瘍細胞に由来し、循環血液内に遊離したDNAなどの核酸(Circulating nucleic acid)を抽出し、1) 画像で診断される以前の微小再発病変の検出や治療効果判定、2) 画像診断にて鑑別が困難な放射線壊死と腫瘍再発の鑑別診断に応用できる可能性を想定した。本年度は正常組織と腫瘍組織由来のDNAの鑑別に有用なDNA異常の検出方法の確立を目指した。このためメチル化特異的PCR法でのP16, MGMT遺伝子のメチル化, P53, PTEN遺伝子などの変異を摘出術で得られた神経膠腫サンプルを用いてスクリーニングをおこなった。上記の遺伝子変化はある程度腫瘍特異的な変化であると考えられる結果が得られ、腫瘍由来のCirculating nucleic acidのマーカーとなる可能性が考えられた。また本検討では血清中に含まれるごく微量のCirculating nucleic acidを検体として用いるため高い検出感度、特異度を必要とする。このためにDNAの抽出、メチル化特異的PCR、変異検出のための塩基配列決定法について様々な条件設定を行い至適条件を検討した。腫瘍特異的なCirculating nucleic acidの検出は複数の変異を検出することで確立できたと思われたが、血清が得られた症例数が少なくまとまった結果は得られなかった。しかし今後症例の蓄積とともに新たな知見が得られるものと考えられた。

  7. ドキソルビシン・リポソームの対流強化輸送法への応用 Competitive

    Toshihiro Kumabe

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Exploratory Research

    2007 - 2009

    More details Close

    抗癌活性を持つ薬剤の脳内局所投与の臨床応用にあたって、「投与薬剤の脳内における分布の把握」および「霊長類における投与薬剤の最大耐用量の把握」は重要な課題である。本年度も昨年度より引き続きドキソルビシン含有高分子ミセルおよびガドリニウム含有高分子ミセルを用いて、脳内の薬剤分布の解析および脳毒性の解析を行った。(1) 脳内薬剤分布の解析 : 正常カニクイザルの脳内にCED法によりドキソルビシン含有高分子ミセルを投与し、投与量(Volume of infusion : Vi)に対する分布容積(Volume of distribution : Vd)の関係を解析した。薬剤分布はガドリニウム含有高分子ミセルを混じることでMRIを用いて薬剤注入と同時にリアルタイムで行った。前年度の結果と同様、Viと直線的な比例関係のVdが得られ、追加して行った3回の薬剤注入によって算出されるVd/Vi ratioは3.27(range 2.45-4.03)であった。この結果により薬剤注入量によって薬剤分布がある程度制御可能であることが明らかとなった。(2) 脳毒性の解析 : 本年度は薬剤分布のマーカーとして用いるガドリニウム含有高分子ミセルの毒性を主に解析した。前述の脳内薬剤分布の解析と同様に正常カニクイザルの脳内にCED法により1mMガドリニウム含有高分子ミセルを投与し、その後、カニクイザルの神経学的異常の有無・体重減少の有無等の観察を行った。薬剤注入の2週間後および半年後に安楽死させ病理組織学的な脳毒性の解析を行った。病理切片はHE染色の他にGFAP、NFP、S-100、およびKB染色を行い評価した。結果、経過観察中にガドリニウム含有高分子ミセルを投与されたカニクイザルは神経脱落症状や体重減少なく経過し、病理組織学的に異常所見は呈さなかった。この結果によりガドリニウム含有高分子ミセルによって安全に薬剤分布のモニタリングが可能となり、高分子ミセル抗癌剤の薬剤分布モニタリングに応用できる可能性が示唆された。

  8. レーザー衝撃波液体ジェットメスを用いた穿通枝温存下神経膠腫摘出術の開発 Competitive

    Toshihiro Kumabe

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Scientific Research (B)

    2007 - 2008

    More details Close

    病変内部を通過する細動脈温存と腫瘍の最大摘出を両立し得るレーザージェットメスを開発した。当研究組織における医工学の各担当チーム間で、工学実験による理論付け・条件出し→臨床応用→フィードバックを行った。神経膠腫手術では操作性、安全性、有効性(血管径100μm程度の細動脈温存)を確認、最終目標である島弁蓋部の穿通枝を巻き込む症例での使用開始に至った。低侵襲脳外科の臨床応用(拡大経蝶形骨洞到達法)、腹腔鏡下疾患(胆嚢摘出、肝臓切開、消化管(食道・胃・小腸・大腸)粘膜下剥離術)の臨床応用に向けた動物実験も行った。

  9. 膠芽腫(グリオブラストーマ)の腫瘍幹細胞に関する研究 Competitive

    Masayuki Kanamori

    Offer Organization: Ministry of education, culture, sports, science and technology

    System: Grant-in-Aid for Young Scientists (B)

    2006 - 2007

    More details Close

    研究の目的)乏突起膠腫の検体を用いて腫瘍幹細胞の分布、増殖、浸潤能について解析を行い臨床情報との相関を検討した。研究実績)本検討では組織学的に乏突起膠腫群と診断された連続56例を対象とした。組織診断は乏突起膠腫13例、退形成乏突起膠腫26例、乏突起星細胞腫5例、退形成乏突起星細胞腫12例であった。生検術、摘出術後、化学療法を42例(75%)および局所照射による放射線治療を49例(88%)に施行し、MRIによる経過観察を行った。WHO分類による悪性度、免疫組織化学的検討により腫瘍幹細胞のマーカーの1つであるNestinの他、p53、MGMT、Ki-67陽性率、CD44の発現パターン、Fluorescent in situ hybridization(FlSH)法による第1及び19染色体欠失の有無について解析し、全生存期間、無再発期間、無播種生存期間との相関を検討した。再発形式は11例が局所再発、9例が播種再発であった。播種再発では全例が死亡し再発後の生存期間は局所再発と比較して統計学的に有意に短かった。解析した因子の中で単変量解析では第1及び19染色体欠失、p53陽性率10%以下、Ki-67陽性率25%以下、Nestinの低発現が全生存、無再発生存、無播種生存において予後良好因子と判定された。多変量解析では生存においては第1及び19染色体欠失、p53陽性率10%以下、播種、局所再発をふくむすべての再発においてはp53陽性率10%以下、Ki-67陽性率25%以下、Nestinの低発現、播種再発においてはKi-67陽性率25%以下、Nestinの低発現が独立した予後良好因子と判定された。以上より腫瘍幹細胞のマーカーの1つであるNestinがびまん性に発現し、また増殖能が高い腫瘍で予後不良な播種再発はの危険性が高いことが示唆された。このことは術後の放射線化学療法の計画に有用な情報を与えるものと考えられる。

Show all Show first 5

Teaching Experience 6

  1. がん医療研修コース（インテンシブ）　山形大学医学部

  2. 東北大学病院がんセミナー　東北大学

  3. 医学解剖学　東北大学保健学科

  4. 老年看護通論　東北大学保健学科

  5. 臨床実習前臨床手技演習　東北大学医学部

  6. 脳神経外科通論講義　東北大学医学部

Show all Show first 5

Other 4

  1. 神経膠腫組織での2-hydroxyglutarate検出法の確立

    More details Close

    神経膠腫組織での2-hydroxyglutarate検出法の確立

  2. 神経膠腫におけるストレス応答

    More details Close

    神経膠腫におけるストレス応答

  3. 悪性脳腫瘍におけるストレス応答系の関与に関する検討

    More details Close

    悪性脳腫瘍におけるストレス応答系の関与に関する検討

  4. 神経膠腫の術中迅速診断、血清診断

    More details Close

    神経膠腫の術中迅速診断、血清診断